็™ป้Œฒใ—ใฆๆ‹›ๅพ…ใƒชใƒณใ‚ฏใ‚’ๅ…ฑๆœ‰ใ™ใ‚‹ใจใ€ๅ‹•็”ปๅ†็”Ÿๅ ฑ้…ฌใจ็ดนไป‹ๅ ฑ้…ฌใ‚’็ฒๅพ—ใงใใพใ™ใ€‚

Wall St Engine
@wallstengine
Fast, accurate, consistent stock market news, earnings highlights & more. By Brillinsight. Not financial advice.
ๅ‚ๅŠ  March 2022
999 ใƒ•ใ‚ฉใƒญใƒผไธญ    224.6K ใƒ•ใ‚กใƒณ
ANGIODYNAMICS $ANGO Q1โ€™27 EARNINGS HIGHLIGHTS ๐Ÿ”น Revenue: $80.9M (Est. $80.5M) ๐ŸŸข; +6.9% YoY ๐Ÿ”น Adj. EPS: -$0.04 (Est. -$0.11) ๐ŸŸข ๐Ÿ”น Gross Margin: 59.4%; +410 bps YoY Affirms FY27 Guide: ๐Ÿ”น Revenue: $336.0M-$341.0M (Est. $337M) ๐ŸŸก ๐Ÿ”น Adj. EPS: -$0.29--$0.24 (Est. -$0.27) ๐ŸŸก ๐Ÿ”น Adj. EBITDA: $13.0M-$16.0M (Est. $13.8M) ๐ŸŸก ๐Ÿ”น Gross Margin: 54% to 55% ๐Ÿ”น Med Tech Growth: 12% to 15% ๐Ÿ”น Med Device Growth: Flat Cash Flow: ๐Ÿ”น Cash from Operations: $15.3M used Segment Net Revenue: ๐Ÿ”น Med Tech: $39.9M; +13.2% YoY ๐Ÿ”น Med Device: $41.0M; +1.4% YoY ๐Ÿ”น Auryon: $18.9M; +14.7% YoY ๐Ÿ”น Mechanical Thrombectomy: $12.0M; +6.7% YoY ๐Ÿ”น NanoKnife: $8.3M; +29.0% YoY Announcements: ๐Ÿ”น CEO: Eric Honroth appointed effective November 2, 2026 ๐Ÿ”น FDA IDE approval for the RELIEF study evaluating NanoKnife IRE for benign prostatic hyperplasia Other Q1 Metrics: ๐Ÿ”น Adj. EBITDA: $5.0M (Est. $1.3M) ๐ŸŸข; +127% YoY ๐Ÿ”น Cash: $34.0M; debt-free balance sheet Comments: ๐Ÿ”ธ โ€œMed Tech again led our growth, highlighted by Auryon's 21(st) consecutive quarter of double-digit atherectomy growth, continued performance in Mechanical Thrombectomy, and ongoing strength in our NanoKnife oncology platform.โ€ ๐Ÿ”ธ โ€œI'm pleased to share that Eric Honroth will become our next President and Chief Executive Officer. He brings the right experience and leadership to build on the foundation we've established, and I will remain closely involved to ensure a smooth transition.โ€
ใ‚‚ใฃใจ่ฆ‹ใ‚‹